In total, the RGA-mediated disruption of these two important angiogenesis signaling pathways (i.e., PI3K-AKT-mTOR and MAPK signaling pathways) likely lead a prolongation of anti-angiogenic properties of bevacizumab (Avastin®), an anti-VEGF often used to treat AMD (Figure 7). The gene discussed is MTOR; the disease is age-related macular degeneration.